8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

July 29, 2010
Date of Report (Date of earliest event reported)


ZOLL MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	0-20225	04-2711626
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

269 Mill Road, Chelmsford, MA  01824

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:(978) 421-9655

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

This Current Report on Form 8-K may contain forward-looking statements within the meaning of the federal securities laws.  Reliance should not be placed on forward-looking statements because they involve known and unknown risks and uncertainties which may cause the actual results, performance, and achievements of ZOLL Medical Corporation (the “Company”) to differ materially from the anticipated future results, performance and achievements that are expressed or implied by such forward-looking statements.  Additional information concerning these risks and uncertainties are contained in the Company’s press release filed as Exhibit 99.1 and in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K filed on December 10, 2009, and in the Company’s other public filings.  The Company disclaims any obligation to update any of the forward-looking statements contained herein to reflect future developments or events.

Item 2.02 Results of Operations and Financial Condition.

On July 29, 2010, ZOLL Medical Corporation (“ZOLL”) issued a press release announcing its results for the quarter ended July 4, 2010.  A copy of the press release concerning these results is furnished herewith as Exhibit 99.1 and is incorporated by reference.

Pursuant to General Instructions B.2 of Form 8-K, this exhibit is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.

Item 9.01 Financial Statements and Exhibits.

  (c) Exhibits.

Exhibit No.	Title
99.1	ZOLL Medical Corporation press release dated July 29, 2010 entitled “ZOLL Medical Corporation Announces Third Quarter Results”

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ZOLL MEDICAL CORPORATION
Date:	July 29, 2010	By:	/s/ Richard A. Packer
			Richard A. Packer
			Chief Executive Officer

EX-99.1

Exhibit 99.1

ZOLL Medical Corporation Announces Third Quarter Results

~Profits Rebound on Record Third Quarter Revenues ~

CHELMSFORD, Mass.--(BUSINESS WIRE)--July 29, 2010--ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2010 increased 17% to $111.3 million, compared to revenues in the third quarter of last year of $95.1 million. The third quarter 2010 results included approximately $5.0 million of revenue from the Temperature Management business, compared to $1.9 million of revenue in the third quarter of last year. The Temperature Management business includes the assets which were acquired from Alsius Corporation in May 2009. Net income was $5.7 million for the quarter, an increase of 285%, compared to $1.5 million in the prior year. Diluted earnings per share were $0.26, compared to $0.07 in the prior year. Backlog at the end of the third quarter was approximately $14 million, as compared to approximately $10 million at the end of Q3 2009.

Third quarter sales to the North American market were $81.9 million, an increase of 13%, compared to $72.8 million for the prior-year period. Due to less Military business, sales to the North American hospital market decreased 8%, to $24.5 million (including $2.6 million related to the Temperature Management business), compared to $26.6 million for the same period last year. Excluding Military and Temperature Management revenues, North American hospital sales increased 9%, compared to the same period last year. US Military sales were $3.4 million in the third quarter of fiscal 2010, compared to $8.8 million for the same period in the prior year.

Sales to the North American pre-hospital market increased 26% to $51.1 million, compared to $40.5 million in the prior year. International sales, including $2.4 million related to the Temperature Management business, increased 31% to $29.4 million, compared to $22.4 million last year. LifeVest® revenues increased 51% to $18.0 million. Total AutoPulse® sales decreased 6% to $3.8 million, compared to $4.1 million in the third quarter of last year.

Gross margin for the third quarter was 54%, compared to 51% in the third quarter of fiscal 2009. The increase primarily reflected improved pricing in the North American core defibrillator business.

Richard A. Packer, Chief Executive Officer of ZOLL, commented, “We were pleased with our results again this quarter as we achieved high growth with the LifeVest and Temperature Management products. We continue to make modest progress with the core business, where once again International results were strong and the US market continues to be a bit of a challenge.”

Mr. Packer stated, “The prospects for both our LifeVest and Temperature Management businesses are very bright. As planned, we resumed adding to the LifeVest sales force, which will help keep us on track to achieve our growth rate of 60% for the year. In Germany, we continue to work through the transition of both these businesses from the previous distributor partners to ZOLL’s own direct efforts. This transition has slowed our sales growth in the short term, but we can already see positive momentum building in this key market.”

With respect to the LifeVest product, Mr. Packer noted, “The recent publication of aggregate experience with the LifeVest, from over 3,500 patients, by Dr. Chung of the Cleveland Clinic, in the Journal of American College of Cardiology adds significantly to the growing body of clinical evidence supporting regular use of the LifeVest. The noteworthy results included patient compliance greater than 90%, first treatment shock conversion efficacy at 99%, and survival during LifeVest use at over 99%. We expect this data, and the associated editorial, to aid our efforts to gain widespread use of the LifeVest by the cardiology community.”

Mr. Packer further commented, “The core North American hospital again showed modest growth as that market rebounds slowly. We received very little Military business during the quarter, as our customers wait on FDA clearance of the new military product, which we now believe is imminent. A large shipment to Canada, which standardized the EMS system in Newfoundland to ZOLL, helped us achieve growth in the North American EMS market in spite of continued spending constraints in the US. We remain cautious about the outlook for the EMS market in the US.”

Mr. Packer observed, “Adding further to the strength of our International prospects, we were pleased to announce, via a separate release, that we have received approval from the Japanese authorities for the AED Plus^® and AED Pro^®. Getting our unique biphasic waveform approved has taken many years, virtually locking our defibrillators out of the large Japanese market. We look forward to announcing a distribution agreement with a significant partner in the near future and beginning shipments before the end of the year. The Japanese market represents another significant growth opportunity for ZOLL.”

Mr. Packer also noted, “During the quarter, one of the challenges facing our International business was foreign exchange. We did experience negative foreign exchange movements within Q3, but we were able to offset those adverse effects with a discrete tax benefit that significantly reduced this quarter’s tax rate.”

Mr. Packer concluded, “Overall, Q3 was continued progress. Our bottom line is growing strongly as the core business rebounds and profitability builds in the newer product lines. We look forward to finishing the year on plan, and we look forward to 2011 where we expect to make additional strides in growing our profitability.”

ZOLL will host a conference call on Thursday, July 29, 2010 at 10:30 a.m. EDT to discuss its third quarter financial results. This conference call will be accessible on the Company’s home page at www.zoll.com. Recorded replays of this conference call will be available on the web page beginning later that day.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, our belief regarding revenues, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2010. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

© 2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse, LifeVest, AED Plus, AED Pro and ZOLL are registered trademarks of ZOLL Medical Corporation. All trademarks are property of their respective owners.

(Financial Results to Follow)

ZOLL MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
	July 4, 2010		September 27, 2009
ASSETS
Current assets:
Cash and cash equivalents	$	59,116	$	51,061
Short-term investments		4,080		7,583
Accounts receivable, net		80,201		80,535
Inventory		74,762		69,700
Prepaid expenses and other current assets		21,802		21,240
Total current assets		239,961		230,119
Property and equipment, net		49,262		40,640
Other assets, net		99,916		101,088
	$	389,139	$	371,847
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current and other liabilities:
Accounts payable	$	24,508	$	20,036
Accrued expenses and other liabilities		62,342		71,253
Total liabilities		86,850		91,289
Total stockholders’ equity		302,289		280,558
	$	389,139	$	371,847

ZOLL MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
	Three Months Ended				Nine Months Ended
	July 4, 2010		June 28, 2009		July 4, 2010		June 28, 2009
Net sales	$	111,326	$	95,147	$	323,596	$	277,317
Cost of goods sold		51,243		46,428		148,642		133,540
Gross profit		60,083		48,719		174,954		143,777
Expenses:
Selling and marketing		32,954		29,148		97,037		83,329
General and administrative		9,059		8,016		27,973		23,642
Research and development		11,570		10,763		34,225		28,848
Total expenses		53,583		47,927		159,235		135,819
Income from operations		6,500		792		15,719		7,958
Other income		122		1,334		348		702
Income before taxes		6,622		2,126		16,067		8,660
Tax expense		885		636		4,364		2,494
Net income	$	5,737	$	1,490	$	11,703	$	6,166
Earnings per share:
Basic	$	0.27	$	0.07	$	0.55	$	0.29
Diluted	$	0.26	$	0.07	$	0.54	$	0.29
Weighted average common shares:
Basic		21,445		21,086		21,343		21,075
Diluted		21,859		21,194		21,675		21,204

CONTACT:
ZOLL Medical Corporation
A. Ernest Whiton, 978-421-9655
Chief Financial Officer